Novo Nordisk’s full year net sales grew by 26% to DKK 290.4bn (Danish Kroner) when ignoring currency movements. Growth was slightly ahead of market forecasts, underpinned by a 27% uplift in the core Diabetes & Obesity Care division.
Operating profit grew in line with sales to DKK 128.3bn. Free cash flow fell from a DKK 68.3bn inflow to an outflow of DKK 14.7bn, as a ramp up in investment spending more than offset improved cash generation. At the year end, Novo Nordisk was carrying net debt of DKK 76.5bn.
Dividend pay outs increased 21% to DKK 50.6bn while share buybacks fell 33% to DKK 20.2bn.
For 2025, sales growth is expected to be 16-24%, and operating profit growth is expected to be 19-27%.
The shares were up 3.2% in morning trading.
Our view
HL view to follow.
Novo Nordisk key facts
All ratios are sourced from Refinitiv, based on previous day’s closing values. Please remember yields are variable and not a reliable indicator of future income. Keep in mind key figures shouldn’t be looked at on their own – it’s important to understand the big picture.
This article is not advice or a recommendation to buy, sell or hold any investment.No view is given on the present or future value or price of any investment, and investors should form their own view on any proposed investment.This article has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is considered a marketing communication.Non - independent research is not subject to FCA rules prohibiting dealing ahead of research, however HL has put controls in place(including dealing restrictions, physical and information barriers) to manage potential conflicts of interest presented by such dealing.Please see our full non - independent research disclosure for more information.